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Abstract
Background: First full term pregnancy (FFTP) completed at a young age has been linked to low long term breast
cancer risk, whereas late FFTP pregnancy age confers high long term risk, compared to nulliparity. Our hypothesis
was that proteins linked to breast cancer would be differentially expressed in human milk collected at three time
points during lactation based on age at FFTP.
Methods: We analyzed breast milk from 72 lactating women. Samples were collected within 10 days of the onset
of lactation (baseline-BL), two months after lactation started and during breast weaning (W). We measured 16
proteins (11 kallikreins (KLKs), basic fibroblast growth factor, YKL-40, neutrophil gelatinase-associated lipocalin and
transforming growth factor (TGF) b-1 and -2) associated with breast cancer, most known to be secreted into milk.
Results: During lactation there was a significant change in the expression of 14 proteins in women < 26 years old and
9 proteins in women > = 26 at FFTP. The most significant (p < .001) changes from BL to W in women divided by FFTP
age (< 26 vs. > = 26) were in KLK3,6, 8, and TGFb2 in women < 26; and KLK6, 8, and TGFb2 in women > = 26. There
was a significant increase (p = .022) in KLK8 expression from BL to W depending on FFTP age. Examination of DNA
methylation in the promoter region of KLK6 revealed high levels of methylation that did not explain the observed
changes in protein levels. On the other hand, KLK6 and TGFb1 expression were significantly associated (r2 = .43,
p = .0050).
Conclusions: The expression profile of milk proteins linked to breast cancer is influenced by age at FFTP. These
proteins may play a role in future cancer risk.
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Background
Immediately following parturition there is an increased
risk of breast cancer observed for all age groups [1].
This is not surprising, since the growth factors required
to allow breast glandular proliferation, as well as the
extensive remodeling required during involution, may
stimulate the growth of already present neoplastic mam-
mary epithelial cell(s). Over the long term, parity is pro-
tective for women whose first full term pregnancy
(FFTP) was completed at a young age (variously defined
as < 20 up to age 26), and increased in parous women
whose FFTP occurred after 35 years of age [2]. Rodent
models suggest that early FFTP leads to changes in the
pattern of breast lobular development and differentia-
tion, cell growth, and gene expression [3]. Early FFTP
imprints a specific genomic signature on the breast [3].
Most studies demonstrate a protective effect of breast
feeding [4], though the influence of breast feeding dura-
tion on cancer risk is less clear, with a recent large
study demonstrating no effect on risk of premenopausal
breast cancer [5]. We think that breast cancer associated
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proteins can provide clues to how early FFTP confers a
protective effect on the breast.
There is good evidence that during involution, which
is initiated by weaning, the breast microenvironment
becomes tumor promotional [6]. Our strategy was to
identify protein biomarkers in breast milk that are asso-
ciated with the protective effect of early FFTP vs. the
cancer promoting effect of late FFTP. We have identi-
fied cancer associated proteins in breast nipple aspirate
fluid, fluid from the milk ducts of nonlactating women,
including kallikrein related peptidases (KLKs) [7,8], basic
fibroblast growth factor (bFGF) [9], and YKL-40 [10].
The KLK family consists of 15 highly conserved serine
proteases. Several members of the family have been
reported as potential cancer biomarkers [11], and many
KLK genes are differentially expressed in hormone-related
malignancies [12]. It has previously been demonstrated
that multiple KLKs are detectable in breast milk [12].
Furthermore, the epigenetic regulation of KLK6 expression
has been demonstrated in hormone sensitive (T47D) and
insensitive (MDA-MB-231) malignant breast cells [13].
bFGF [14] has been detected in human milk, while
YKL-40 (and its bovine homologue, mammary gland
protein (MGP)-40) levels in breast milk rise during the
time of breast involution, as the breast returns to the
prepregnancy state [15]. Neutrophil gelatinase-associated
lipocalin (NGAL, a.k.a. lipocalin 2) is a small secreted
glycoprotein which binds matrix metalloproteinase-9 to
protect it from degradation [16]. NGAL is expressed in
breast carcinomas, inhibition of NGAL impairs breast
tumorigenesis and metastasis [17], and increased NGAL
expression has been associated with decreased disease-
specific survival [18]. The homolog of NGAL has been
identified in cow’s milk [19].
Transforming growth factor (TGF)b is linked to breast
cancer in preclinical models [20] and to prognosis in
human breast cancer [21]. In mouse models, TGFb is
induced during mammary gland lactation and involution
[20], and it mediates proapoptotic effects during involu-
tion [1]. Transgenic mice that overexpress TGFb show
increased apoptosis in the mammary epithelium through-
out mammary development [22]. KLK6 is thought to act
on the TGFb1 signal transduction pathway and thereby
influence cell migration and motility, and KLK6 alters the
expression of TGFb1 in breast cancer cells [23].
The time of weaning, a period of breast involution and
remodeling, appears critical to future breast cancer risk
[6]. The analysis of wean milk will provide essential infor-
mation regarding the biology of markers related to breast
involution. We investigated 16 proteins: 11 KLKs, bFGF,
YKL-40, as well as NGAL and two isoforms TGFb,
which, like bFGF and YKL-40, have been associated with
breast cancer [1,18]. This study was conducted based on
the hypothesis that lactation exerts a protective effect by
upregulating cancer preventing and downregulating can-




Healthy women were prospectively recruited prior to or
soon after delivery. They were eligible if they delivered a
≥ 37 weeks gestation infant and were planning on breast
feeding. After agreeing to enroll in an Institutional
Review Board approved project, three milk samples were
requested from each participant: baseline (BL), defined as
within 10 days of the initiation of lactation, two months
after lactation started, and when the woman is weaning
(W). The participant was asked to provide the wean sam-
ple once they had decided to stop nursing, and had
started to decrease the number of daily feedings. At least
two samples from a given woman were required in order
for the samples to be included in our analyses. Each sam-
ple was collected from the same breast.
Subjects were recruited in Columbia, MO, Grand Forks
and Fargo, ND, after IRB approval. Mothers were asked
not to breast feed their infants for at least two hours
before milk collection, which involves draining the breast
using manual extraction or a breast pump. Samples were
immediately frozen after collection. Collected milk was
thawed, centrifuged (1500 × g, 20 min, 4°C), and the fat
and cellular layers separated. The aqueous phase was
then centrifuged at 12000 g for 15 min at 4°C, the second
lipid layer removed and stored at -80°C prior to analysis.
Assessment of protein biomarkers
Total protein
25 μL of standard and milk samples were added in dupli-
cate to each microplate well (Pierce, Rockford, IL), fol-
lowed by 200 μL of working reagent with mixing. The
microplate was then incubated at 37οC for 30 minutes
and absorbance measured at 562 nm.
KLKs
The concentration of KLKs was measured with a highly
sensitive and specific non-competitive immunoassay.
Each assay incorporated two KLK specific monoclonal
and or polyclonal antibodies (Ab), raised in mouse and
rabbit respectively. One Ab was used for antigen capture
and other for detection (Table 1) in a sequential two site
immunometric format with time resolved fluorescence
detection. KLK2 and KLK3 antibodies were obtained
from MedixBiochemica (Kauniainen, Finland). The
remaining KLK antibodies were developed in the labora-
tory of Dr. Eleftherios Diamandis Director of Clinical
Biochemistry, University of Toronto. The KLK assays
have a detection limit ranging from 0.005 μg/L for KLK3
to 0.2 μg/L for KLK7, 8 and 11 and a dynamic range of
10-20 μg/L, depending on the KLK (Table 1). These
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assays have been used in multiple prior publications
[8,12,24-27]. Standards (recombinant KLK) and samples
were analyzed in duplicate with inclusion of three quality
control samples in every run.
bFGF
bFGF was analyzed using an enzyme linked immunosor-
bant assay (ELISA) kit from R&D Systems (Minneapolis,
MN), following the manufacturer’s instructions. The kit
utilizes a quantitative sandwich enzyme immunoassay
technique. The detection limit of the kit is 10 ng/L.
YKL-40
Samples were analyzed by immunoassay as per the man-
ufacturer’s instructions (Quidel Corporation, San Diego,
CA). The kit uses a monoclonal anti-YKL-40 antibody
conjugated to biotin which binds to streptavidin and cap-
tures YKL-40 in the standard or sample. The detection
limit is 10 ng/mL.
NGAL
NGAL content in milk was measured by immunoassay
(BiPorto Diagnostics, Denmark) according to the manu-
facturer’s instructions. Briefly, 100 μL of standard and
diluted milk samples were added to wells coated with a
monoclonal antibody against human NGAL. Bound
NGAL was detected with a second antibody labeled
with biotin and the signal developed with horseradish
peroxidase-conjugated streptavidin and substrates, the
reaction ended with stop solution and absorbance mea-
sured at 450 nm. The detection limit of the NGAL kit is
4.0 pg/mL.
TGFb isoforms
The protein expression levels of TGFb1 and b2 in milk
samples were determined by immunoassay (R&D Systems)
following the manufacturer’s instructions. Briefly, 50 μL of
standard and activated milk samples were added to wells
in duplicate, incubated for 2 hours at room temperature
(RT), washed and 100 μL of TGFb1 or b2 conjugate
added. Following another wash, 100 μL of substrate solu-
tion was added for 30 min at RT, the reaction ended with
100 μL of stop solution and absorbance measured at
450 nm. The detection limits of the TGFb1 and b2 kits
are 4.61 and 7.0 pg/ml, respectively.
Assessment of KLK6 methylation
DNA Isolation and bisulfite treatment
DNA was isolated from all 42 breast milk cell pellets
that were available from women who underwent KLK6
Table 1 Demographics and Kallikrein Assay Information
Demographics
Total participants (N) 72





4th or greater 7
Age
Mean (median) 28.3 (28)
Range 20-39
Kallikrein (KLK) Assay Information
Kallikrein Assay Configuration1 Dynamic range Detection Limit
(μg/L) (μg/L)
KLK2 Mono-Mono 10 0.01
KLK3 Mono-Mono 10 0.005
KLK4 Mono-Poly 20 0.1
KLK5 Mono-Mono 10 0.05
KLK6 Mono-Mono 20 0.05
KLK7 Mono-Mono 20 0.2
KLK8 Mono-Mono 20 0.2
KLK10 Mono-Mono 10 0.1
KLK11 Mono-Poly 20 0.2
KLK13 Mono-Mono 10 0.1
KLK14 Mono-Poly 10 0.1
1: Assay configuration: The confirmation listed indicates the two antibodies (Ab) used, the first being the antigen capture and the second the detection antibody.
Mono: monoclonal Ab, poly: polyclonal Ab
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protein analysis women using the QIAamp DNA mini
kit (Qiagen, Germantown MD) with the following modi-
fications: 10 μl of RNAse A (1 mg/ml) was added to
each DNA isolation at the beginning of the protocol; at
the end of the protocol an ethanol precipitation was
performed to clean and concentrate the DNA. DNA
quantity and quality were assessed using the NanoDrop
8000 spectrophotometer (Thermo Scientific, Wilming-
ton DE). Up to 500 ng of high quality DNA were bisul-
fite converted using the EpiTect Bisulfite Kit according
to manufacturer’s instructions (Qiagen, Germantown
MD).
KLK6 PCR and pyrosequencing
Two μl of bisulfite converted DNA were used in each PCR
reaction to amplify the promoter region of the KLK6 gene
using the PyroMark PCR kit (Qiagen, Germantown MD).
KLK6 primers were designed to amplify an area of the
promoter region upstream of the transcriptional start site
(TSS). This region includes 4 CpG sites (-72, - 64, -56 and
-53 upstream of TSS) that have been shown to be methy-
lated in breast cancer cell lines and unmethylated in nor-
mal cell lines [13]. Primer sequences are as follows: sense
primer: 5’- GTAAAGGAGGATTGTTAGATAGGG-3’,
antisense primer: 5’-biotin-CCAACACCCCAATACCAT-
3’, sequencing primer: 5’-GATAAAAGGAAGTTATT-
GATG-3’. Pyrosequencing was performed using a Pyro-
Mark Q24 pyrosequencer (Qiagen, Germantown MD) [28]
using PyroGold Reagents (Qiagen, Germantown MD).
Pyrosequencing using mixtures of in vitro methylated and
unmethylated DNA demonstrated a high degree of linear-
ity (R2 = 0.99) for this KLK6 DNA methylation assay.
Statistical analysis
Expression levels of proteins were first logarithm-trans-
formed using natural base prior to analysis. Changes in
protein expression over three time points (BL, 2 months,
W) were tested with longitudinal analysis using a linear
mixed model. P values were adjusted for multiple tests
with Holm’s step-down procedure. For proteins that
showed a significant change over the three time points, a
paired t test was performed to detect the change between
each pair of time points. Regression analysis was carried
out to identify the association between the ages at FFTP
with BL protein levels or change of protein expression
between the three lactation periods. In order to identify
the maximum number of possible associations with FFTP,
we did not adjust p values for multiple tests. The effects of
nursing time on total protein and individual proteins were
assessed using regression analysis. Levels of KLK6 methy-
lation were compared among the three time points using
one-way analysis of variance. The association of KLK6
methylation and protein levels was tested using regression
analysis at each time point and at each CpG site. The
interaction of KLK6 and TGFb1 was analyzed using
regression analysis.
Results
Breast milk samples were collected from 72 women, 35
women for whom it was their FFTP and 37 for whom it
was not (Table 1). One woman enrolled in the study after
breastfeeding for 2 months and no BL milk was available.
A 2 month milk sample was not collected from two
women because they weaned prior to the 2 month time
point. Milk was collected at all three timepoints from
47 women. Wean milk samples were not collected from
25 women (14 have not yet weaned, 9 weaned but did not
provide a wean sample, and 2 were lost to follow-up).
There was considerable variability between samples in
total milk protein concentration. For this reason, all bio-
marker results are listed and all statistical analyses were
conducted controlling for total protein concentration in
the milk sample. Total protein expression was not influ-
enced by either age at FFTP or whether the samples were
collected from a primiparous vs. a multiparous woman.
FFTP age was not found to interact with parity status.
The expression of multiple milk proteins varies during
the course of lactation
For our two milk collection time points, overall (consider-
ing all sample collections) change in individual protein
expression was compared in women with young (< 26
years) vs. older (> = 26 years) age at FFTP (Table 2). Of
the 16 proteins evaluated, there was an overall change in
the expression of 14 (for women < 26) and 9 (for women
> = 26) proteins, respectively.
For proteins with a significant global change, we deter-
mined (Table 2) the change for each of three lactation per-
iods (BL to 2 months, BL to W and 2 months to W).
Mean expression significantly decreased for 8 (for women
< 26) and 8 (for women > = 26) proteins, respectively,
between BL and 2 months, and increased for 13 (for
women < 26) and 11 (for women > = 26) proteins, respec-
tively, between 2 months and W. Between BL and W
there was a highly significant (p < .001) increase in the
expression of KLK6, 8, and TGFb2 in both age groups.
KLK3 expression was lower in W than BL milk of women
< 26 but not those in the > = 26 group.
Expression (and expression change during lactation) of
biomarkers linked to breast cancer are related to age at
FFTP
For each of the 16 proteins, we evaluated the association
of expression with age at FFTP. At BL, bFGF (p = .0116)
and NGAL (p = .012) expression were significantly higher
in women who were older at the time of their FFTP
(Figure 1a,b). There were no significant associations at
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2 months or W. There was a larger increase in KLK8
expression (p = .022) from BL to W (controlling for total
time that a woman nursed) with younger age at FFTP
(Figure 1c).
DNA methylation of KLK6 varies among women and with
breast feeding duration but does not explain protein
expression pattern
To determine the extent to which the changes observed in
KLK6 protein levels were controlled by epigenetc events,
we isolated DNA from a total of 42 breast milk cell pellets
(eight at BL, 13 at 2 months and 21 at W) obtained from
32 women. Methylation analysis by pyrosequencing
revealed high mean levels of KLK6 promoter methylation
at all three time points 57% (BL), 34% (2 months) and 48%
(W), and no significant differences across time points (F =
2.27; p = .117). Among the ten women for whom methyla-
tion was assessed at two time points, there was an average
absolute difference of 37% methylation between the two
sampling times. The greatest differences (Figure 2)
Table 2 Mean Natural Log (ng/g) Values of Baseline (BL), 2 Month (2 Mo) and Wean (W) Samples vs.
Age (yrs) < 26 > = 26
Biomarker BL 2Mo W P (overall) P (pairs)1 BL 2Mo W P (overall) P (pairs)1
KLK2 0.91 0.96 0.89 NS2 NS2 1.03 1.09 0.93 NS NS
KLK3 2.36 1.75 0.80 0.0011 *, ††† 2.42 1.56 1.89 NS *
KLK4 -0.75 -0.68 0.13 0.0088 †, ^ -0.88 -0.65 -0.09 NS ††
KLK5 8.51 7.83 9.17 5.49E-11 **, ^^ 8.43 7.21 8.92 1.22E-10 ***,^^^
KLK6 9.88 10.1 10.9 4.61E-11 ***, †††,^^^ 9.79 9.89 10.6 1.56E-6 †††,^^^
KLK7 5.52 4.45 6.18 0.0039 **, ^^ 5.03 4.79 5.25 NS NS
KLK8 8.10 8.32 9.54 5.16E-10 *,†††.^^^ 7.84 8.20 9.04 1.49E-10 ***,†††,^^^
KLK10 5.18 5.97 7.18 0.0011 **,††,^^ 4.77 5.59 7.15 2.3-4 *,††,^^
KLK11 6.44 4.73 6.57 5.35E-5 ***,^ 6.36 4.95 5.78 0.0049 **
KLK13 2.56 1.87 1.25 NS †,^ 2.11 2.01 1.14 NS NS
KLK14 1.10 0.89 1.46 0.046 ††,^^ 1.18 0.83 1.21 NS ^^
N(all KLKs) 37 36 20 32 33 21
YKL40 12.1 10.6 12.2 2.38E-6 ***,^^ 12.3 10.1 12.0 3.88E-11 ***,^^^
NGAL 8.31 7.23 8.37 4.5E-4 ***,^^ 8.91 7.16 8.36 6.96E-12 ***,^^^
bFGF -1.46 -3.15 -1.91 2.58E-8 ***,^^^ -1.07 -2.89 -1.85 NS ***,††,^^
TGFb1 3.88 3.52 4.23 5.49E-5 **,^^ 3.88 3.36 4.40 2.34E-5 **,†,^^^
TGFb2 5.55 5.25 7.06 7.27E-7 †††,^^^ 5.47 5.03 7.09 2.74E-12 *,†††,^^^
N(non-KLKs) 37 36 21 34 34 26
Age at First Full Term Pregnancy
1: P (pairs): paired comparisons. *: BL vs. 2 Mo; †: BL vs. W; ^: 2 Mo. vs. W. One mark (*, †, or ^): p < 0.05; two marks: p < 0.01; three marks: p < 0.001. P values
adjusted for multiple comparisons using Holm’s step-down procedure
2: NS: not significant. If NS is listed under P (pairs), it indicates that there were no significant associations for any of the three paired comparisons
Figure 1 Natural log a) bFGF and b) NGAL baseline milk expression; or c) change (wean–baseline) in natural log KLK8 milk protein
expression based on age at FFTP. For KLK8, only matched samples are represented.
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occurred between BL and 2 months (mean change for the
6 women = 44%) and between 2 months and W (mean
change for the two women = 42%) with little change
between BL and W (mean change for the two women =
10%). The methylation level was not associated with KLK6
protein level (p = .35).
Association of KLK6 with TFGb1
KLK6 has been reported to interact with the TGFb1 sig-
nal transduction pathway and influence TGFb1 expres-
sion in breast cancer cells [23]. We determined the
association of these proteins in breast milk, considering
all samples for which there were paired values. The two
proteins (Figure 3) were significantly associated (r2 =
.43, p = .0050).
Discussion
One approach to assess the influence of a specific pro-
cess such as age at FFTP is global (proteome wide)
assessment. Unfortunately, this approach has limited
sensitivity [29] even with sample concentration
approaches [30], and lack reliable quantitation of indivi-
dual protein concentration. We elected to use immu-
noassays which are highly sensitive and quantitative, to
compare individual protein expression during the course
of lactation.
A striking feature of the data is that the expression of
most proteins varies during lactation, even after control-
ling for total protein concentration. A similar observation
in a smaller sample was made by another group in the
assessment of milk immunoglobulins and lysozyme [31].
The most common trend that we observed was for the
concentration of proteins to decrease from BL to 2
months after starting nursing, and then to increase
between 2 months and W. Although the reason(s) for
this are uncertain, a possible explanation is that the
breast secretes a given amount of each protein daily, with
greater milk volume during the 2 month lactation period
compared to BL or W periods leading to a lower protein
concentration. Indeed, total milk protein concentration
has been shown to negatively correlate with 24 hour milk
volume [32], and gradual weaning over a period of three
months has been shown to increase total protein as milk
volume decreased [33].
The most significant changes in expression from the
start to the end of lactation in both FFTP age groups were
in KLK6, 8 and TGFb2. There was a significant decrease
in KLK3 in women < 26 at the time of FFTP, but not in
Figure 2 Methylation of KLK6 in DNA isolated from cells obtained from breast milk. The average of the percent of methylated DNA at
each of 4 CpG sites in the proximal promoter of KLK6 is shown for milk samples collected at Baseline (n = 8), Two Months (n = 13), and Wean
(n = 21).
Qin et al. BMC Cancer 2012, 12:100
http://www.biomedcentral.com/1471-2407/12/100
Page 6 of 9
women with a later age of FFTP. The significance of the
change in one but not the other group is uncertain. For
KLK6, 8 and TGFb2, there was a small change early
(between BL and 2 months), with a larger change later
(between 2 months and W) in lactation. For all three pro-
teins there was an increase in mean expression at the time
of weaning compared to BL.
KLK6 and 8 expression is downregulated in breast can-
cers [34]. As such, it has been speculated that these genes
may function to suppress tumors [13]. KLK6 [13] is epi-
genetically regulated with gene silencing in tumors. KLK6
may play a protective role against tumor progression by
inhibiting the epithelial-to-mesenchymal transition [13].
KLK8 has been shown to function as a serine protease
[35]. The mechanism of KLK8 gene silencing in breast
cancer has not been reported, though alternative splice
variants of the gene which influence prognosis have been
reported in lung cancer [36]. The increase in KLK8
expression from BL to W was greatest in women who
whose FFTP occurred at a young age, which is consistent
with known protective effect of early age at FFTP [2] and
a tumor suppressive effect of KLK8.
The significant changes in KLK6 protein expression
during lactation and the report of regulation of KLK6 by
methylation in breast cancer cells [13] prompted us to
examine KLK6 promoter methylation in cells obtained
from breast milk. We detected surprisingly high levels
of KLK6 promoter methylation with moderate differ-
ences among the three sampling times that did not
explain the observed changes in protein expression.
Indeed, the lowest mean level of methylation, 34%,
occurred at 2 months. While we expected low methyla-
tion to be associated with the highest protein expression,
KLK6 expression, on average, was highest in wean milk
for all age categories (Table 2). Whereas methylation
scores were relatively high at all sampling times, repeated
measures from ten women revealed average methylation
changes during lactation of 37%.
To assess the likelihood that the observed variability in
KLK6 methylation throughout lactation was an artifact, we
examined the promoter methylation of p16 (data not
shown), which we would not predict to vary with lactation
duration. In contrast to KLK6, there was little methylation
of p16 at each point, ranging from 1 to 5%, indicating that
the variability in KLK6 methylation is not likely to be an
artifact. It is important to note that, unlike the prior report
associating KLK6 methylation with KLK6 expression in
cultured malignant breast cells [13], our clinical investiga-
tion evaluated breast cells collected from the breasts of
healthy women. Regarding the variability in KLK6 methy-
lation which we observed, we believe that this is at least
partly due to differing percentages of epithelial cells and
leucocytes that were present in the milk at the three sam-
pling times, since DNA was isolated from the total cell
pellet. Nonetheless, we confirmed that epithelial cells pre-
sent in milk from healthy breasts have high levels of
methylation by examining several epithelial-enriched cell
fractions (data not shown).
Whereas we did not find a association between KLK6
methylation and protein expression, we did observe a
highly significant association between KLK6 and TGFb1
protein expression. TGFbs regulate normal breast devel-
opment, apoptosis and matrix remodeling during breast
involution induced by breast weaning, with biphasic
effects on tumor progression, acting as tumor suppres-
sors in early stages of cancer and promoting invasion
and metastasis at later stages [37]. Our observation that
the expression of these proteins are directly correlated,
whereas they are inversely associated in breast cancer
cells in culture [23], is consistent with the pleiotropic
effects of these molecules to suppress cancer initiation
and promote later stages of cancer invasion and
metastasis.
This report has limitations. Most notable is the limited
sample of women whose FFTP was age 35 or greater, as
well as the limited BL and 2 month sample sizes for the
methylation analyses. We may have missed associations
with age at FFTP due to this. A second limitation is that
there was some variability between when the wean milk
sample was collected and when the woman stopped nur-
sing entirely. A third limitation is that we cannot say
with certainty that the proteins identified which are
upregulated at the time of weaning would put these
women at lower risk of future breast cancer, since we
do not have sufficient follow-up to address this. On the
other hand, as previously discussed, we know from
other reports that higher expression of KLK 6, 8, 10 and
TGFb2 have been associated with a lower risk of breast
cancer [34,38].
Figure 3 Association of natural log TGFb1 and KLK6 protein
expression in breast milk.
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Conclusions
We report the upregulation of KLK 6, 8 and TGFβ2 at the
time of breast weaning and involution. All four proteins
have a tumor suppressive effect, consistent with the
known protective effect of pregnancy in younger women.
KLK8 levels were generally lower at BL in women older at
the time of their FFTP, but the change was greater in
these women, suggesting a protective correction toward a
higher KLK8 expression level by the end of lactation.
bFGF and NGAL expression was higher in BL lactation
samples among women with an older age of FFTP. Both
are tumor promotional, consistent with the association of
late FFTP with increased breast cancer risk. Finally, we
observed a significant association between KLK6 and
TGFβ1, which may be one mechanism by which these
molecules interact during lactation to influence future
breast cancer risk. We plan to investigate these proteins in
the nipple aspirate fluid of women with and without breast
cancer, to see if their expression is associated with disease.
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